R&D Bolstering CAR-T therapies by tackling CRS, with Teresa Whal... In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome
Digital Agentic AI buoys all stakeholders in oncology, with Eron Kel... At LSX 2025, Eron Kelly, CEO of Concert AI, discussed the work his Boston-based start-up is doing in oncology.
R&D A different approach to obesity treatment, with Steffen-Seba... At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.
R&D Why Regeneron is giving away sequencing “for free”, with Ali... Alison Fenney, executive director of strategic partnerships and business operations at Regeneron Genetics Center, discusses free genetic sequencing.
Oncology News and advice from an investor-CEO, with Milenko Cicmil pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.
R&D Driving innovation through partnership at AstraZeneca, with ... Nikhil Mutyal, head of search and evaluation for respiratory and immunology at AstraZeneca, discusses partnership and external innovation at LSX.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.